CIK 0001815776 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
LENZ Therapeutics, Inc.
Sign in to watch- Ticker
- LENZ
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 844867570
- Phone
- 858-925-7000
- Business address
- 201 LOMAS SANTA FE DRIVE, SUITE 300, SOLANA BEACH, CA, 92075
- Former names
- Graphite Bio, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $9,134,778
- in 1 filing
Net −$9,134,778. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-07-22 | Schimmelpennink Evert B. President, CEO and Secretary | Option exercise · Stock Option (right to buy) | −45,000 | 342,106 | ||
| 2024-05-14 | Chevallard Daniel R. Chief Financial Officer | Purchase | +3,188 | $15.68 | $50K | 3,188 |
| 2024-05-13 | MCCOLLUM JAMES W Director | Purchase | +31,332 | $15.99 | $501K | 525,565 |
| 2024-03-21 | Thunen Shelley B Director | Grant or award · Stock Option (right to buy) | +27,000 | 27,000 | ||
| 2024-03-21 | MCCOLLUM JAMES W Director | Grant or award | +95,034 | 95,034 | ||
| 2024-03-21 | MCCOLLUM JAMES W Director | Grant or award | +477,600 | 477,600 | ||
| 2024-03-21 | MCCOLLUM JAMES W Director | Grant or award | +16,633 | $15.03 | $250K | 494,233 |
| 2024-03-21 | MCCOLLUM JAMES W Director | Grant or award · Warrant (right to buy) | +6,575 | 6,575 | ||
| 2024-03-21 | MCCOLLUM JAMES W Director | Grant or award · Stock Option (right to buy) | +27,000 | 27,000 | ||
| 2024-03-21 | Guerard Frederic Director | Grant or award · Stock Option (right to buy) | +30,897 | 30,897 | ||
| 2024-03-21 | Guerard Frederic Director | Grant or award · Stock Option (right to buy) | +23,571 | 23,571 | ||
| 2024-03-21 | Guerard Frederic Director | Grant or award · Stock Option (right to buy) | +27,000 | 27,000 | ||
| 2024-03-21 | Drapkin Kimberlee C Director | Grant or award · Stock Option (right to buy) | +27,000 | 27,000 | ||
| 2024-03-21 | George Jeffrey P. Director | Grant or award · Stock Option (right to buy) | +27,000 | 27,000 | ||
| 2024-03-21 | Chevallard Daniel R. Chief Financial Officer | Grant or award · Stock Option (right to buy) | +200,000 | 200,000 | ||
| 2024-03-21 | Olsson Shawn Chief Commercial Officer | Grant or award · Stock Option (right to buy) | +67,974 | 67,974 | ||
| 2024-03-21 | Olsson Shawn Chief Commercial Officer | Grant or award · Stock Option (right to buy) | +30,466 | 30,466 | ||
| 2024-03-21 | Olsson Shawn Chief Commercial Officer | Grant or award · Stock Option (right to buy) | +50,915 | 50,915 | ||
| 2024-03-21 | Olsson Shawn Chief Commercial Officer | Grant or award · Stock Option (right to buy) | +105,000 | 105,000 | ||
| 2024-03-21 | Odrich Marc Chief Medical Officer | Grant or award | +99,599 | 99,599 |
Page 5 of 11 · 217 trades